Optimal Antithrombotic Therapy for Patientswith STEMI Undergoing
Optimal Antithrombotic Therapy for Patientswith STEMI Undergoing
复制标题
STEMI 患者的最佳抗血栓治疗
DOI：
--
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
Qingchun Zeng
中科院分区：
文献类型：
--
作者：
Yan Tu;Lu Hu;Chanjuan Yang;Arash Nemat;Gaopeng Xian;Jierong Zhang;Qingchun Zeng
PurposeofReview Inthereview,webrieflydescribeantithromboticdrugsandtheuseevidencefromevidence-basedmedicineto.elucidate the optimal antithrombotic management for patients with ST-segment elevation myocardial infarction (STEMI) under-.going percutaneous coronary stenting (PCI) at high risk of bleeding..RecentFindings Mandatoryuseofintravenousanticoagulantsanddualantiplateletagentsisthecornerstonestrategyinacuteand.long-term antithrombotic management to optimize the clinical benefit of patients with STEMI undergoing PCI. Nevertheless,.with the increasing occurrence of STEMI in old population with high risk of bleeding and renal insufficiency, as well as the.specificity of high bleeding risk groups, the optimization of antithrombotic therapy still remains uncertain..Summary Bivalirudin is the optimized intravenous anticoagulant agent for these patients based on the guideline recommenda-.tionsandclinicdata.Timelyandpotentticagrelorandprasugrelwithaspirinusagecanincreasetheclinicalbenefitforthepatients.without increasing the clinical bleeding risk. At present, the multi-center, prospective clinical studies of EVOLVE short DAPT,.MASTER DAPT, and POEM trials, targeting patients with high risk of bleeding, are in experimental stage. These clinical trials.will provide more objective and optimal antithrombotic management strategy for the patients.
